After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

Even as the US faces major outbreaks of Cyclospora and Salmonella infections, the Food and Drug Administration (FDA) has finalized safety guidance for operations handling ready-to-eat (RTE) fresh-cut produce.

The guidance incorporates public comments received on the October 2018 draft and replaces the FDA’s 2008 guidance on fresh-cut produce.

“This guidance represents the agency’s current thinking on the issues related to preventing contamination in fresh-cut produce,” the FDA said.

The agency also encouraged the industry to continue advancing food safety practices, including through best-practice documents tailored to specific commodities and processes.

The FDA’s guidance targets manufacturers and processors of fresh-cut produce and recommends measures such as sanitation controls, supplier verification and refrigeration amid ongoing outbreaks of cyclosporiasis and salmonella linked to fresh produce.

What Does the FDA Guidance Include?

The FDA recommendations are not legally binding and are aimed at manufacturers and processors of products such as chopped lettuce, sliced cantaloupe, diced onions, shredded carrots, coleslaw mixes and fruit salads.

Fresh-cut produce can include a single commodity, such as cut lettuce, sliced cantaloupe, diced celery, diced onions and shredded carrots, or combinations of two or more produce items, such as coleslaw mixes and fruit salads.

The FDA has focused on contamination with pathogens including salmonella, cyclospora, E. coli and listeria.

Fresh-cut produce processors should assess whether these pathogens pose potential hazards that require preventive measures, including supply-chain controls, the FDA said.

The recommended measures include:

• Using safe water
• Washing fruits and vegetables with antimicrobial solutions
• Training personnel
• Improving facility design
• Implementing sanitation controls
• Verifying suppliers
• Maintaining appropriate refrigeration

Why Is Fresh-Cut Produce at Risk?

Fresh-cut produce can be particularly susceptible to contamination because pathogens may be introduced at multiple points, including during growing, transportation, manufacturing, commingling with other products or at retail.

The opportunity for contamination can increase at each stage before the food reaches consumers.

Fresh-cut produce also does not undergo a kill step to eliminate pathogens that may be introduced during these processes, and most products are sold ready to eat.

The guidance provides recommendations and examples of how Preventive Controls for Human Food can be implemented to protect fresh-cut RTE produce from biological hazards.

Cyclospora and Salmonella Outbreaks

The guidance comes as the US investigates outbreaks linked to contaminated lettuce and jalapenos that have sickened thousands of people.

The cyclospora outbreak linked to iceberg lettuce from Taylor Farms has spread to 15 states, with Michigan hit the hardest.

“Americans should feel confident in eating fresh produce, including leafy greens at this point,” Diamantas said during an appearance on CNBC. The FDA said it remains confident that iceberg lettuce linked to the cyclospora outbreak had been effectively removed from the market following the July 17 recall.

The US Department of Health and Human Services also said Tuesday on X: “Cyclospora: contained, American food: safe.”

However, the FDA and CDC say the investigation into the cyclospora outbreak remains ongoing.

Separately, Taylor Farms said Monday that it was recalling prepared foods containing jalapenos from retailers in several states because of potential salmonella contamination.

Statins are widely used to lower “bad” LDL cholesterol and reduce the risk of heart attacks and strokes.

A new study published in The Lancet Healthy Longevity found that stopping statins in adults aged 75 and older with no history of cardiovascular disease did not increase the risk of death over three years compared with continuing treatment.

However, LDL cholesterol rose by around 50% among those who stopped taking the drugs.

Stopping Statins Did Not Increase Death Risk

The study found no significant difference in deaths or major cardiovascular events, including heart attacks and strokes, between older adults who stopped statins and those who continued treatment.

Researchers cautioned that the findings do not mean older adults should routinely stop taking statins.

“The decision to continue or stop statin treatment later in life should be individualized and made through shared decision-making between patients and clinicians,” the researchers said.

Further trials are needed to confirm the findings and assess the long-term effects of stopping statins.

“The benefits of statins increase over time in younger adults and it remains unknown whether stopping the medication could increase the risk of cardiovascular disease and death after the three-year follow-up period in older people,” said the researchers from Bordeaux University Hospital and Université de Bordeaux, France.

What Did the Trial Find?

The randomized controlled trial enrolled 1,160 adults aged 75 and older with no history of heart disease or stroke at general practices in France. Participants were randomly assigned to stop or continue their statin medication.

After three years:

• 7.2% (35/484) in the statin discontinuation group had died.
• 7.9% (48/604) in the continuation group had died.
• There was no significant difference in major cardiovascular events, including heart attacks and strokes.
• LDL cholesterol rose by 50%, from 115 mg/dL to 171 mg/dL, among those who stopped statins.
• LDL cholesterol showed no change among those who continued treatment.
• Physical and mental quality of life remained unchanged in both groups.

What Does This Mean for Patients?

The study involved people taking statins for primary prevention—those at risk of heart disease or stroke but without established cardiovascular disease.

The researchers stressed that the findings should not be interpreted as a recommendation to stop statins.

Instead, the decision should be based on the individual patient’s circumstances and discussed with a clinician.

Why Are Findings Important?

Evidence on the benefits of statins for primary prevention in older adults remains limited because many statin trials exclude people older than 70 or 80.

A 2013 Cochrane meta-analysis of 18 trials found a 14% reduction in deaths from all causes among adults taking statins for primary prevention of atherosclerotic cardiovascular disease. However, the median age of participants was 57.

The new findings also differ from observational studies from Denmark and Italy published in 2021. Those studies reported about a 30% higher risk of fatal and nonfatal cardiovascular outcomes after statins were discontinued in older adults.

Unlike those cohort studies, the new research was a randomized controlled trial, but it only followed participants for three years.

How Statins Work

Statins work by reducing the amount of cholesterol produced by the liver, helping slow the buildup of fatty plaque in the arteries.

They are prescribed both for people at risk of cardiovascular disease (primary prevention) and those with established cardiovascular disease (secondary prevention).

The new study does not establish that stopping statins is safe for all adults over 75. Longer-term research is needed to determine whether discontinuing treatment could affect cardiovascular risk or mortality beyond three years.

The U.S. Social Security Administration (SSA) has expanded its Compassionate Allowances (CAL) program by adding 14 serious and rare medical conditions, helping eligible patients to have their disability claims fast-tracked.

The announcement, made on August 11, brings the total number of conditions covered under the programme to 314. According to the SSA, more than 1.2 million people with severe disabilities have been approved through the fast-paced process since CAL was introduced.

Which Conditions Have Been Added To CAL?

The newly included conditions range from rare genetic and neurological disorders to aggressive cancers. They include:

• Aicardi Syndrome
• Baraitser-Winter Syndrome
• Bohring-Opitz Syndrome
• CASK-Related Gene Disorders
• Lafora Disease
• Warburg Micro Syndrome
• Hepatosplenic T-Cell Lymphoma
• Primary Cardiac Sarcoma
• Primary Intracranial Malignant Melanoma
• Metastatic Uveal Melanoma
• Malignant Migrating Partial Seizures of Infancy
• OPHN1 Syndrome
• Beare-Stevenson Cutis Gyrata Syndrome
• Adenylosuccinate Lyase Deficiency, neonatal form and Type 1

Also read: Trump Signs Order To Change Childhood Vaccine Schedule Amid Measles Outbreak, Split MMR Into Three Shots

What Is The Compassionate Allowances programme?

For people with severe disabilities, applying for Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) can become another burden at a time when they are already dealing with a life-changing diagnosis.

The CAL programme, established in 2008, is designed to reduce the waiting time. When a person applies for disability benefits with a qualifying condition, the SSA can identify the diagnosis and move the claim through an accelerated determination process. In some cases, decisions can take days rather than months due to red tape.

The programme is particularly important for patients whose illnesses may prevent them from working while simultaneously creating significant medical and financial expenses.

Also read: Kennedy Announces Food Policy Reforms Under Trump’s MAHA Agenda: What Has Been Proposed?

How Can This Expansion Help?

Rare diseases and aggressive cancers can progress rapidly, leaving patients and families with little financial breathing room. A conventional disability determination can involve gathering medical records and reviewing evidence before a decision is made.

“The Compassionate Allowances initiative cuts through red tape and allows us to deliver support to individuals who experience life-changing diagnoses and need help fast,” SSA Commissioner Frank J. Bisignano said.

The agency said it uses technology to identify potential CAL conditions and, where available, receives electronic medical records through its Health IT programme to help adjudicators make faster decisions.

Also read: Donald Trump Mulls Order Targeting Childhood Vaccines And Autism

What Does This Change Mean For Patients?

The most important factor patients must note is that CAL is not a separate benefit or extra payment. It is a faster route through the existing SSDI and SSI disability determination process. Patients must still meet Social Security's definition of disability and other eligibility requirements.

There is also no separate CAL application. Patients should apply for SSDI or SSI and ensure their qualifying diagnosis is clearly documented. The SSA system can then flag eligible claims for accelerated processing of their claims.

For families facing rare, devastating diseases, that difference can be significant. Faster access to existing disability benefits can help bridge the gap between a diagnosis that changes someone's ability to work and the financial support they need to manage life after it.